A special issue of the journal Tuberculosis was released today, outlining a strategic new vaccine plan to advance solutions for tuberculosis. Â With over 10 million children globally affected by the disease, more effective vaccines are thought to be crucial in battling TB by attempting to protect infants at birth. Â A vaccine is also desired to protect those with latent TB from developing symptomatic, active disease.
â€œThe TB Vaccine Blueprint provides an enormous opportunity to coordinate efforts to halt the spread of this devastating disease,â€� said Dr. Aaron Motsoaledi, the Minister of Health of South Africa. â€œGovernments have an important role to play, and guided by this common strategy we will do our part to make a vaccine a reality.â€�
â€œThe new blueprint represents the best thinking of the field,â€� said Dr. Jelle Thole, director of the TuBerculosis Vaccine Initiative (TBVI) and co-editor of the blueprint with Dr. Michael J. Brennan, senior advisor for scientific and global affairs at Aeras. â€œIt makes clear that the next 10 years will be vital in moving forward the global search for a dramatically improved vaccine against tuberculosis.â€�
Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade was developed as part of the Stop TB Partnership Working Group on New Vaccines with support from the World Health Organization, Bill & Melinda Gates Foundation, Aeras, TuBerculosis Vaccine Initiative, the EC FP 7 framework programme and the US National Institutes of Health, National Institute of Allergy and Infectious Diseases. The complete blueprint, including relevant opinion editorials, was published in the journal Tuberculosis (Brennan, MJ and Thole, J, Vol. 92, Supplement 1, ppS1-S35, March 2012).